Tyme Overview

Tyme Inc. is an emerging biotechnology company developing metabolic-based cancer therapeutics that are intended to be broadly effective across a range of tumor types, while maintaining patient’s quality of life with relatively low toxicity profiles. Unlike targeted therapies that attempt to regulate specific pathways within cancer, Tyme’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic requirements to compromise its defenses, leading to cell death and exposure to the body’s immune system.

Tyme has built an experienced management team and distinguished board of directors to lead the company on its important mission to extend cancer patients’ lives with improved quality of life. The company continues to build strong collaborations with leading academic institutions that include Mt. Sinai, the Mayo Clinic and many other notable institutions.

Our lead clinical program, SM-88, is a novel oral monotherapy investigational agent. SM-88 is studied in use with three other drugs: methoxsalen, phenytoin, and sirolimus (hereafter, referred to as SM-88 used with MPS). SM-88 used with MPS’s profile is supported to date by over 5 years of clinical data in more than 100 metastatic cancer patients. SM-88 used with MPS is currently in Phase II development for prostate and pancreatic cancer and Tyme is preparing to initiate pivotal studies for SM-88 used with MPS in pancreatic cancer. The TYME-88-Panc study is intended to be a pivotal trial studying SM-88 used with MPS in third-line pancreatic cancer. SM-88 used with MPS will also be studied in the Pancreatic Cancer Action Network Precision Promise study as both monotherapy and in combination with standard of care. Tyme is also preparing to support the initiation of an investigator-initiated trial in sarcoma in early 2019 in partnership with Dr. Sant Chawla and in collaboration with the Joseph Ahmed Foundation (JAF). Initiation of trials in other metastatic cancers are being considered for later in 2019.

Tyme Inc. has multiple formulations for SM-88 in their pipeline, including injectable, intranasal, and transdermal that are expected to be advanced into the clinical setting over time.

Tyme Inc. maintains a broad intellectual property portfolio of issues and pending patents covering our technologies and products well into the 2030’s.

TYME Factsheet

(View PDF)